title: A novel liposomal formulation of flavopiridol.
abstract: Flavopiridol has shown promising activities in hematologic and solid tumor models, as well as in clinical trials in chronic lymphocytic leukemia patients. Flavopiridol has relatively low solubility and high plasma protein-binding. To address these issues and to provide an alternative strategy to achieve clinical efficacy, we encapsulated flavopiridol into a liposomal carrier and characterized its physicochemical and pharmacokinetic properties. The liposomes, comprising hydrogenated soy phosphatidylcholine (HSPC), cholesterol and poly (ethylene glycol) 2000-distearoyl phosphatidylethanolamine (PEG-DSPE), were prepared by polycarbonate membrane extrusion and then loaded with flavopiridol by a pH-gradient driven remote loading procedure. The liposomes had a mean diameter of 120.7 nm and a flavopiridol entrapment efficiency of 70.4%. Pharmacokinetic study in mice after i.v. bolus injection showed that the liposomal flavopiridol had an increased elimination phase half-life (T((1/2)beta), 339.7 min vs. 57.0 min), decreased clearance (CL, 0.012 L/min vs. 0.036 L/min), and increased area under the plasma concentration-time curve (AUC, 10.8 min micromol/L vs. 3.4 min micromol/L) compared to the free drug. This indicates a significant and potentially beneficial change in flavopiridol pharmacokinetics for the liposomal formulation. Further preclinical studies are warranted to define the toxicity and therapeutic efficacy of this novel formulation.
authors.affiliation: Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Xiaojuan
authors.initials: X
authors.lastname: Yang
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Zhao
authors.forename: Mitch A
authors.initials: MA
authors.lastname: Phelps
authors.forename: Longzhu
authors.initials: L
authors.lastname: Piao
authors.forename: Darlene M
authors.initials: DM
authors.lastname: Rozewski
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.forename: L James
authors.initials: LJ
authors.lastname: Lee
authors.forename: Guido
authors.initials: G
authors.lastname: Marcucci
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grever
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.forename: James T
authors.initials: JT
authors.lastname: Dalton
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Lee
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D004337:Drug Carriers / Q000737:chemistry*; D005419:Flavonoids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006207:Half-Life; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D008081:Liposomes; D051379:Mice; D008813:Mice, Inbred ICR; D010713:Phosphatidylcholines / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D010880:Piperidines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011076:Polycarboxylate Cement / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D013025:Glycine max / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D005419:Flavonoids; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010880:Piperidines; D011076:Polycarboxylate Cement; C107570:polyethylene glycol-distearoylphosphatidylethanolamine; C005506:polycarbonate; D011092:Polyethylene Glycols; C077990:alvocidib
references.citation: Leuk Lymphoma. 2002 Apr;43(4):793-7
references.pmid: 12153166
references.citation: Ann Oncol. 2003 Aug;14(8):1270-3
references.pmid: 12881391
references.citation: J Clin Oncol. 2002 Oct 1;20(19):4074-82
references.pmid: 12351605
references.citation: Oncologist. 2002;7  Suppl 3:12-9
references.pmid: 12165651
references.citation: Anticancer Drugs. 2005 Aug;16(7):691-707
references.pmid: 16027517
references.citation: Clin Cancer Res. 2001 Jun;7(6):1590-9
references.pmid: 11410495
references.citation: J Pharm Sci. 1999 Sep;88(9):945-7
references.pmid: 10479359
references.citation: Blood. 2007 Jan 15;109(2):399-404
references.pmid: 17003373
references.citation: PDA J Pharm Sci Technol. 1996 Nov-Dec;50(6):356-9
references.pmid: 9038080
references.citation: J Clin Oncol. 1998 Sep;16(9):2986-99
references.pmid: 9738567
references.citation: Clin Cancer Res. 2004 Feb 1;10(3):924-8
references.pmid: 14871968
references.citation: Leukemia. 2001 Jan;15(1):1-9
references.pmid: 11243375
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):4176-81
references.pmid: 15930354
references.citation: Ann Pharmacother. 2002 May;36(5):905-11
references.pmid: 11978170
references.citation: Crit Rev Oncol Hematol. 2001 May;38(2):139-70
references.pmid: 11311660
references.citation: Invest New Drugs. 2004 Aug;22(3):315-22
references.pmid: 15122079
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 1;868(1-2):110-5
references.pmid: 18490204
references.citation: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95
references.pmid: 14508085
references.citation: Leuk Res. 2005 Nov;29(11):1253-7
references.pmid: 15916806